An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales.

OBJECTIVES To survey of the structure, processes and organisation of renal satellite units (RSUs) in England and Wales (Phase 1), and to compare the effectiveness, acceptability, accessibility and economic impact of chronic haemodialysis performed in RSUs compared to main renal units (MRUs) (Phase 2). DATA SOURCES Phase 1: all renal satellite units in England and Wales. Phase 2: haemodialysis patients in a representative sample (based on geography, site, private--public ownership, medical input) of 12 RSUs and their MRUs. REVIEW METHODS Phase 1 consisted of a questionnaire survey. Semi-structured interviews were held in a representative sample of 24 RSUs with the senior clinician, senior nurse and manager. Phase 2 consisted of a cross-sectional comparison of patients in these RSUs and patients in the parent MRUs deemed suitable for satellite care by senior staff. Clinical information was obtained from medical notes and unit computer systems. Generic and disease specific health-related quality of life (HRQoL) measures were used. Co-morbidity was assessed by the Wright/Khan Index, the Lister/Chandna score, the Modified Charlson Index, and the Karnofsky Performance Score. Statistical analyses compared RSU versus MRU patients and took account of the paired and clustered nature of the data. RESULTS In Phase 1, responses were received from 74/80 (93%) of RSUs; 2600 patients were being treated in these RSUs. The interviews were generally positive about the impact of RSUs in terms of improved accessibility and a better environment for chronic haemodialysis (HD) patients, and in expanding renal replacement therapy patients (RRT) capacity. In Phase 2, some 82% of eligible patients took part, 394 patients in the 12 RSUs and 342 in the parent MRUs. The response rate was similar in both groups. There were no significant differences in clinical processes of care. Most clinical outcomes were similar, especially after pooled analysis, although a few parameters were statistically significantly different -- notably the proportion achieving Renal Association Standards for adequacy of dialysis as measured by the urea reduction ratio (URR) was higher in the RSU patients. Patient-specific quality of life did not differ except on the patient satisfaction questions from the KDQOL, which were scored higher by the RSU sample. Strength of preference for health status on and off dialysis was very similar between the groups, as were EQ-5D utilities. Major adverse events were not common in the RSU patients, although there were many hypotensive episodes on HD, a proportion of which affected the duration of the HD session. Of the costs measured, the only difference that was statistically significant was for District Nurse visits. Of particular note was that despite the MRU group having a higher proportion of patients hospitalised, this did not translate into a statistically significant budgetary impact in terms of the total cost per patient of hospitalisations or mean cost per patient per hospitalisation. CONCLUSIONS This study has shown that RSUs are an effective alternative to MRU HD for a wide spectrum of patients. They improve geographic access for more dispersed areas and reduce patients' travel time, and are generally more acceptable to patients on several criteria. There does not seem to be an adverse impact of care in the RSUs although comparative long-term prospective data are lacking. The evidence suggests that satellite development could be successfully expanded; not all MRUs have any satellites and many have only a few. No single RSU model can be recommended but key factors would include local geography, the likely catchment population and the type of patients to be treated. There is a need for more basic budgetary information linking activity and expenditure to be available and more transparent, to perform at least an insightful top-down costing of the two care settings. Other areas suggested for further research include: a comparison of adverse events occurring in MRUs and RSUs with longer duration and larger numbers to identify more severe events, along with the more research into the scope for preventing such events, and a study into the patients deemed ineligible for satellite care. International comparisons of satellite care would also be useful.

[1]  G. Warwick,et al.  Albumin as an outcome measure in haemodialysis in patients: the effect of variation in assay method. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  P. Stevens,et al.  Assessment of quality of life in a single centre dialysis population using the KDQOL-SF questionnaire. , 2000, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.

[3]  J. Ehrich,et al.  Report on management of renal failure in Europe, XXIII. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  M. Rothstein,et al.  Vascular access thrombosis in new hemodialysis patients. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  L. Wright Survival in patients with end-stage renal disease. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  M. Garraway,et al.  Can different patient satisfaction survey methods yield consistent results? Comparison of three surveys , 1996, BMJ.

[7]  S G Thompson,et al.  The design and analysis of paired cluster randomized trials: an application of meta-analysis techniques. , 1997, Statistics in medicine.

[8]  R. Hays,et al.  Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument , 1994, Quality of Life Research.

[9]  R. Gokal Treatment of Adult Patients with Renal Failure: Recommended Standards and Audit Measures , 1995, Journal of the Royal College of Physicians of London.

[10]  H. Feldman,et al.  Hemodialysis vascular access morbidity. , 1996, Journal of the American Society of Nephrology : JASN.

[11]  K. Farrington,et al.  Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity , 1999, BMJ.

[12]  R. Wolfe,et al.  The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study , 2000 .

[13]  J. Walls,et al.  Analysis of Patients Dying within One Year of Starting Renal Replacement Therapy , 2000, American Journal of Nephrology.

[14]  M. Abdalla,et al.  The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? , 1993, BMJ.

[15]  E G Lowrie,et al.  The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. , 1993, The New England journal of medicine.

[16]  A. Grant,et al.  Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. , 2005, The Cochrane database of systematic reviews.

[17]  Chris Jones,et al.  Predicting future demand in England, a simulation model of renal replacement therapy , 2002 .

[18]  R. Wolfe,et al.  Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  R. Wolfe,et al.  Vascular access use in Europe and the United States: results from the DOPPS. , 2002, Kidney international.

[20]  D. Churchill,et al.  Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure. , 1993, Nephron.

[21]  E. Friedman,et al.  Pervasive failed rehabilitation in center-based maintenance hemodialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  D. Karnofsky The clinical evaluation of chemotherapeutic agents in cancer , 1949 .

[23]  G A de Wit,et al.  Economic evaluation of end stage renal disease treatment. , 1998, Health policy.

[24]  W. J. Johnson,et al.  Functional status of patients with end-stage renal disease. , 1987, Mayo Clinic proceedings.

[25]  F. Port,et al.  Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  M. Saul,et al.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. , 2000, The American journal of medicine.

[27]  W. Keane,et al.  Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Charles Normand,et al.  Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study , 2000, The Lancet.

[29]  P. Roderick,et al.  What Determines Geographical Variation in Rates of Acceptance onto Renal Replacement Therapy in England? , 1999, Journal of health services research & policy.

[30]  C. Sherbourne,et al.  The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. , 1994 .

[31]  N. Jones,et al.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire , 1993, Quality of Life Research.

[32]  唐乐莲,et al.  Microsoft Excel , 2004 .

[33]  J T Daugirdas,et al.  The dose of hemodialysis and patient mortality. , 1996, Kidney international.

[34]  B. Hollingsworth,et al.  Efficiency measurement of health care: a review of non‐parametric methods and applications , 1999, Health care management science.

[35]  D. Churchill,et al.  Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. , 1992, American journal of nephrology.

[36]  M. Calnan,et al.  Convergence and divergence: assessing criteria of consumer satisfaction across general practice, dental and hospital care settings. , 1991, Social science & medicine.

[37]  J. Tokars,et al.  A prospective study of vascular access infections at seven outpatient hemodialysis centers. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  J R Morris,et al.  The Sickness Impact Profile: Conceptual Formulation and Methodology for the Development of a Health Status Measure , 1976, International journal of health services : planning, administration, evaluation.

[39]  J. Kopple Effect of nutrition on morbidity and mortality in maintenance dialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  David Parkin,et al.  Measuring production efficiency of acute hospitals in Scotland, 1991-94: validity issues in data envelopment analysis , 1997 .

[41]  A. Nissenson,et al.  National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  W. McClellan,et al.  Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. , 1991, Journal of clinical epidemiology.

[43]  R. Hays,et al.  A review of health-related quality-of-life measures used in end-stage renal disease. , 1996, Clinical therapeutics.

[44]  A. Coulter,et al.  Criterion validity and reliability of the SF-36 in a population sample , 1994, Quality of Life Research.

[45]  J. Dettori,et al.  Health technology assessment , 2009, International Journal of Technology Assessment in Health Care.

[46]  C D Mistry,et al.  Incidence of advanced chronic renal failure and the need for end stage renal replacement treatment. , 1990, BMJ.

[47]  T. Hutchinson,et al.  Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. , 1979, Journal of chronic diseases.

[48]  G. Bonsel,et al.  Test-retest reliability of health state valuations collected with the EuroQol questionnaire. , 1994, Social science & medicine.

[49]  I. Khan,et al.  Influence of coexisting disease on survival on renal-replacement therapy , 1993, The Lancet.

[50]  E. Friedman,et al.  Predictive Value of Functional Status for Mortality in Patients on Maintenance Hemodialysis , 1998, American Journal of Nephrology.

[51]  P S Kurtin,et al.  Monitoring dialysis patients' health status. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[52]  J. Bergström Nutrition and mortality in hemodialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[53]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[54]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[55]  N. Powe,et al.  Septicemia in dialysis patients: incidence, risk factors, and prognosis. , 1999, Kidney international.

[56]  A. Stewart,et al.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. , 1989, JAMA.

[57]  A Donner,et al.  Confidence interval construction for effect measures arising from cluster randomization trials. , 1993, Journal of clinical epidemiology.

[58]  David C. Murray,et al.  Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. , 1996, Kidney international.

[59]  D Parkin,et al.  The efficiency of Scottish acute hospitals: an application of data envelopment analysis. , 1995, IMA journal of mathematics applied in medicine and biology.

[60]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[61]  P. Roderick,et al.  The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. , 1998, QJM : monthly journal of the Association of Physicians.

[62]  J. Ware SF-36 health survey: Manual and interpretation guide , 2003 .

[63]  Paul Kind,et al.  UK population norms for EQ-5D , 1999 .

[64]  J. Etienne,et al.  Lp(a) is increased in hemodialysis patients according to the type of dialysis membrane: a 2-year follow-up study. , 2000, Clinical nephrology.

[65]  R. Wolfe,et al.  Body size, dose of hemodialysis, and mortality. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[66]  J. Brazier,et al.  The SF36 as an outcome measure of services for end stage renal failure. , 1998, Quality in health care : QHC.